Previous Close | 1.8300 |
Open | 1.8300 |
Bid | 1.9400 |
Ask | 2.1200 |
Strike | 31.00 |
Expire Date | 2024-11-15 |
Day's Range | 1.8300 - 2.1400 |
Contract Range | N/A |
Volume | |
Open Interest | 1.48k |
NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.
NEW YORK, September 17, 2024--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, October 29, 2024. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2024 Performance Report, to be issued that morning.
The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.